We searched for BMP6 mutations in relatives of 5 probands and in 200 healthy individuals (controls), as well as in two other independent cohorts of hyperferritinemia patients.
We measured serum levels of hepcidin by liquid chromatography-tandem mass spectrometry and analyzed BMP6 in liver biopsies from patients by immunohistochemistry. The functions of mutant and normal BMP6 were assessed in transfected cells using immunofluorescence, real-time quantitative PCR, and immunoblot analyses.
RESULTS: We identified 3 heterozygous missense mutations in BMP6 (p.Pro95Ser, p.Leu96Pro, and p.Gln113Glu) in 6 unrelated patients with unexplained iron overload (9% of our cohort). These mutations were detected in less than 1% of controls. The p.Leu96Pro was also found in 2 patients from the additional cohorts. Family studies indicated dominant transmission. Serum levels of hepcidin were inappropriately low in patients. A low level of BMP6, compared with controls, was found in a biopsy from 1 patient. In cell lines, the mutated residues in the BMP6 propeptide resulted in defective secretion of BMP6; reduced signaling via SMAD1, SMAD5, and SMAD8; and loss of hepcidin production.
CONCLUSIONS: We identified 3 heterozygous missense mutations in BMP6 in patients with unexplained iron overload. These mutations lead to loss of signaling to SMAD proteins and reduced hepcidin production. These mutations might increase susceptibility to mild-to-moderate late onset iron overload.
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INTRODUCTION
Hereditary hemochromatosis (HH) is an iron overload disorder reflecting mutations in different
genes encoding proteins involved in the regulation of hepcidin production. Hepcidin acts as a negative regulator of duodenal iron intake [1] and iron recycling from spleen and liver macrophages [2, 3] . HH is characterized by abnormal iron loading in parenchyma, leading to liver cirrhosis, cardiomyopathy, diabetes, hypogonadism and arthralgia [4, 5] although only a few HH patients suffer from overt disease. Currently, the main therapeutic approach is a regular phlebotomy to remove excess iron [6] .
Hepcidin synthesis in the liver is controlled by serum iron levels and tissue iron stores through an "iron-sensing complex" comprising the integral proteins HFE, hemojuvelin (HJV) and the type 2-transferrin receptor (TFR2). This complex acts through the bone morphogenetic protein (BMP)/SMAD1/5/8-signaling complex to induce hepcidin-encoding gene (HAMP) expression when too much iron is available [7] . Hepcidin synthesis is also induced by inflammatory signals such as IL-6 and plays a major role in the anemia of chronic diseases [8, 9] . In contrast, HAMP gene is negatively regulated through the serine protease matriptase 2, which cleaves HJV and disrupts BMP/SMAD signaling [10] [11] [12] . In European Caucasian populations, HFE is responsible for the most common form of adult-onset HH, while HAMP, HJV and TFR2 genes are responsible for the rare (<1 %) early-onset subtypes of HH, showing the rapid and severe progression of iron overload [5, 13] . In rare cases, dominant mutations in the iron exporter ferroportin (FPN) gene can also lead to an iron overload phenotype [14] [15] [16] [17] . Nevertheless, there are many patients with iron overload in whom no causative mutation in the known hemochromatosis genes has been identified [18] .
BMPs belong to the TGF-β family and are involved in both osteogenic (bone and cartilage) and non-osteogenic developmental processes [19] . The BMP6 gene (6p24-p23) has seven exons, encoding a large precursor of 513 amino acids (aa), comprising an N-terminal signal peptide sequence, a prodomain for proper folding, and a C-terminal secreted mature peptide sequence of 138 aa ( Figure 1A ). BMP6 is also a key regulator of hepcidin expression and iron metabolism [20] [21] [22] . This protein cooperates with HJV to bind to BMP type I and type II receptors and induces the phosphorylation of SMAD 1/5/8 proteins, which subsequently interact with SMAD4. This complex translocates to the nucleus, where it binds the HAMP promoter and stimulates HAMP gene transcription. Recent studies have shown that Bmp6-deficient mice develop a severe iron overload [20, 22] , suggesting that BMP6 might be a candidate gene in patients with severe HH not attributable to HJV or HAMP genes [20, 22] . However, because no BMP6 mutations have been reported, we postulated that, in humans, these mutations might be responsible for a mild late-onset phenotype rather than severe iron overload phenotype. Therefore, we analyzed the BMP6 gene in a series of 70 patients with primary mild to moderate iron overload in whom mutations in known HH M A N U S C R I P T
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4 genes had been excluded. Identified BMP6 mutations were additionally found in two other independent cohorts of hyperferritinemia patients. supplementary Table S1 ) and presented with high ferritinemia and elevated liver iron concentration (LIC > 36 mol/g as confirmed through Magnetic Resonance Imaging (MRI) analysis). Cases with hyperferritinemia of known origin were excluded: chronic or acute inflammatory syndrome, transfusions, cellular lysis, dysmetabolic syndrome, and excessive alcohol consumption. Genetic analyses had previously ruled out defects in HFE (C282Y homozygous, compound C282Y/H63D heterozygous), TFR2 and FPN genes. Serum hepcidin was measured in all samples with a previously validated LC-MSMS method [23] .
MATERIALS and METHODS
BMP6
All patients and healthy controls were Caucasians of western continental French descent, originating from the Ile de France region. Written informed consent was obtained for all participants, and this study was approved through the local ethical committees.
The replication cohort consisted of a prospective nationwide study from 2011 to 2013. Inclusions criteria were persistent increase of serum iron and serum transferrin saturation (>50%) at two separate tests, and LIC > 100 mol/g. Exclusion criteria were HFE C282Y homozygous mutation, history of transfusion, bloodletting, hematological disease, or history of iron supplementation.
Coding sequence of the genes HAMP, HJV, TFR2, HFE, SLC40A1 and BMP6 were sequenced.
Serum hepcidin levels were determined with an enzyme immunoassay (Peninsula Laboratories, Bachem, San Carlos USA). Table S2 .
HAPLOTYPE ANALYSIS
Haplotype analysis was performed with two microsatellite markers surrounding BMP6 gene (22_AC and 16_GT, supplementary Table S2 ). Polymerase chain reactions (PCRs) were performed using 20 ng of genomic DNA and the products were analyzed using the ABI Prism 3130 Genetic Analyzer and Gene Mapper analysis software v4.0 (Life technologies). Table   S2 .
BMP6 CONSTRUCTIONS AND MUTAGENESIS
BMP6 (NM_001718
IMMUNOHISTOCHEMICAL TESTING
Liver tissue samples were fixed in 10% formalin buffer, embedded in paraffin, sectioned, and stained with Perls' Prussian blue or with the primary anti-BMP6 (S-20) antibodies (1/50; Santa Cruz Biotechnology, inc. CliniSciences, Nanterre, France) diluted in PBS-1% BSA and 1% FCS.
Immunohistochemistry was performed using an automated immunohistochemical stainer according to the manufacturer's guidelines (streptavidin-peroxidase protocol, BenchMark, Ventana).
CELL ANALYSES
Opossum Kidney (OK) cells (ATCC®, LGC STANDARDS, Molsheim, France) were cultured in Eagle's Minimum Essential Medium (EMEM) (ATCC®, LGC STANDARDS, Molsheim, France) containing 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen-Gibco). HepG2 cells (ATCC®, LGC STANDARDS, Molsheim, France) were grown in M A N U S C R I P T
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6 DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin. HuH7 cells were cultured in DMEM with L-glutamine and 1 g/L glucose, supplemented with 10% heat decomplemented FBS, 100 U/mL penicillin, and 100 g/mL streptomycin (Invitrogen-Gibco). The human hepatocarcinoma cell line Hep3B (ATCC®, LGC STANDARDS, Molsheim, France) was grown in DMEM, 10% fetal calf serum, 100 U/mL penicillin, and 100 g/mL streptomycin (Invitrogen-Gibco). All cell lines were transfected using the X-tremGENE HP DNA Transfection Reagent (Roche Diagnostics, Mannheim, Germany), according to manufacturer's instructions.
Transfected culture were then washed and maintained in the serum-free medium until reaching confluence (1-2 days after transfection). 
IMMUNOBLOTTING AND IMMUNOPRECIPITATION
For protein cell extraction, cells were harvested by incubation during 60 min in ice-cold RIPA buffer (0.05 M Tris-HCl at pH 7.6, 0.15 M NaCl, 1% w/v Triton X-100, 0.1% SDS, 1mM EDTA) containing 1x protease inhibitor cocktail (Complete, Roche). The cell lysates were then centrifuged at 4°C x 12,000 g for 15 min to recover the protein pellet. For secreted proteins, the serum freesupernatants were filtered through centrifugal filter unit (Amicon Ultra-4 centrifugal filters, Millipore, Paris, France) and concentrate samples were recovered and stored. HAMP and Id1 and BMP6 transcripts were amplified with specific primers (supplementary Table   S1 ). In parallel, β2M transcripts were amplified with specific primers and detected in a similar manner to serve as an internal control. Standard curves for HAMP, Id1, BMP6 and β2M were generated from accurately determined dilutions of cDNA. Samples were analysed in duplicate for each experiment, and results are reported as the ratio of mean values for hepcidin or Id1 to β2M.
STATISTICAL ANALYSIS
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A two-tailed Student's t-test and Chi-square test were used with a P value of < 0.05 determining statistical significance. 95% confidence intervals for the odds ratio were calculated. GraphPad
InStat software (GraphPad Software, San Diego, CA) was used for statistical evaluation.
RESULTS
Patient characteristics
In a cohort of 70 patients with moderate unexplained iron overload, we found six individuals, five males and one female, carrying one heterozygous BMP6 mutation. The most relevant clinical and biological data of these patients are shown in Table 1 . The patients were over 50 years of age (mean age 57.5, 50-65), with elevated serum ferritin, normal or high transferrin saturation and elevated LIC. Perl's staining of the liver biopsies from patient 4 showed significant iron overload in both hepatocytes and Kupffer cells ( Figure 1D ). Five out of six patients were treated through phlebotomy, removing 1.5-5 g of total iron. Serum hepcidin was measured through LC-MSMS spectrometry. Although the results were not available for all patients, the patients with BMP6
mutations had normal or only slightly elevated serum hepcidin levels, despite the presence of excess liver iron (Table 1) . Family studies were performed for five patients ( Figure 2 ) and additional carriers of a mutation were identified, some of them also showing moderate signs of iron overload (Patient II.2, Family 5). We also measured serum hepcidin in two young asymptomatic carriers available (III.1 and 2, family 1) who exhibited normal iron status. Their serum hepcidin levels were normal (data not shown).
Altogether, these results suggested that these heterozygous BMP6 mutations conferred susceptibility to iron overload, although younger carriers were not iron overloaded and women appeared to be protected from iron overload. They also appeared to aggravate the iron load resulting from additional factors such as overweight (proband 4, LIC 230 mol/g) or moderate alcohol intake (proband 5, LIC 220 mol/g), two conditions known to lead to moderate iron excess (LIC<150 mol/g [24] ).
Identification of BMP6 mutations
The BMP6 mutations that we identified were located in exon 1: c.283C>T (p.Pro95Ser, one patient), c.287T>C (p.Leu96Pro, three patients), and c.337C>G (p.Gln113Glu, two patients). These three mutations were located in the propeptide domain and affected amino acids highly conserved throughout species (Figure 1 A-C) . These three BMP6 mutations were also present in some individuals of European American Caucasian descent (39 out of 8000 alleles) found in the Exome Variant Server (http://evs.gs.washington.edu/EVS/, see supplementary Table S3 ), albeit at a nine times lower frequency than in our cohort of patients (6 out of 140 alleles, P<0.00001). Thus, BMP6 mutations were highly associated with an iron overload phenotype in the studied patients (OR 9.62, figure S1 ). We found that eight patients who carried the BMP6 p.Leu96Pro mutation did not share a unique haplotype, consistent with the hypothesis of multiple independent mutational events.
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Replication cohort analysis
Sixty two patients were initially included. Two of them were later excluded, one because of HFE p.Cys282Tyr homozygous mutation found at sequencing and one because of low serum transferrin saturation at inclusion. One patient (R1) had the p.Leu96Pro mutation (table 1) . She presented metabolic syndrome with diabetes, porphyria cutanea tarda and the HFE p.His63Asp mutation. As in proband 4 and proband 5 of the first cohort, the presence of the BMP6 mutation seemed to exacerbate the liver iron overload (250 mol/g), over the level normally observed in metabolic syndrome [24] . Although one cannot rule out the possibility that p.His63Asp HFE mutation might contribute to the accumulation of excess iron in the liver, this mutation is not usually considered as pathogenic in the absence of the p.Cys282Tyr mutation [25] . One patient (R2) had the p.Gln113Glu mutation (table 1) . He had no other comorbidities than moderate dyslipidemia and presented with elevated serum ferritin and serum transferrin saturation since three years.
Additional cohort analysis
Ten patients were initially included. We identified one Caucasian patient with only one heterozygous p.Leu96Pro BMP6 mutation without any modification in the other genes. We confirmed the presence of this mutation by Sanger sequencing and verified that HFE, HJV, TFR2, HAMP and SLC40A10 genes were not affected. The patient exhibited signs of moderated iron overload including elevated serum ferritin (968 g/L), transferrin saturation (52%) and LIC (95 mol/g). Family history of this patient showed that his son also exhibited an unexplained hyperferritinemia.
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Functional analysis of BMP6 mutations
Because the mutations identified in the patients studied were all located in the propeptide region, we expected these mutations to alter BMP6 protein folding and/or secretion. When we analyzed the BMP6 staining in the liver biopsies obtained from patient 4, we observed reduced levels of BMP6 protein in hepatocytes compared with control biopsies ( Figure 3A) , with apparent protein retention in the compartments surrounding the nucleus. We tried to measure the protein level of BMP6 in the serum of patients, but we found that circulating BMP6 was undetectable both in BMP6 patients and Figure S3) . These data were additionally confirmed in two other hepatocyte cell lines Hep3B ( Figure 5C ) and HuH7 (Supplementary Figure S3) .
Furthermore, because BMP6 assembles as a dimer and patients carrying mutations are heterozygotes, we co-expressed BMP6-WT and the p.Leu96Pro-mutant in HepG2 cells. The mutated protein co-expressed with BMP6-WT failed to induce hepcidin production to the same extent as the mutated protein alone compared with BMP6-WT alone ( Figure 6A ), suggesting a dominant-negative mechanism. Therefore, we investigated whether BMP6 mutants interact with BMP6-WT. We co-transfected OK cells with constructs expressing V5-BMP6 along with BMP6-
WT (DDK-WT) or with pLeu96Pro-BMP6 (DDK-M). Immunoprecipitation (IP) and Western
blotting were then performed as described in methods. Figure 6B clearly showed that similarly to BMP6-WT, pull-down of DDK-M using anti-DDK antibody results in co-precipitation of V5-BMP6. Co-IP controls confirming specificity of the interaction between WT and mutanted-BMP6
proteins (including isotype IgG control and cells in which only V5-BMP6 was transfected and then anti-DDK immunoprecipitation was performed) are shown in Supplementary Figure S4 . These results suggest that despite the mutation, BMP6 mutants conserved their ability to form heterodimers with BMP6-WT. Thus, we hypothesized that BMP6 mutations may lead to intracellular retention of WT/mutant heterodimer proteins. Taken together, these data suggested that BMP6 propeptide mutations might reduce BMP6 secretion, thereby leading to impaired hepcidin production in the liver.
DISCUSSION
In the present study, we report for the first time that heterozygous BMP6 defects in humans can lead to a mild to moderate late-onset iron overload phenotype, showing both elevated serum ferritin levels and increased liver iron stores. These observations differed from those in mice, where homozygous Bmp6 inactivation induced severe iron overload [20, 22] . However, in the present study, the patients were heterozygous for the BMP6 defect, and the mutation induced a change in the propeptide region that did not fully inactivate the protein. This new BMP6-related disorder resembled classical hemochromatosis in several respects: there were more affected males than females, iron excess was present only in carriers of BMP6 mutations aged 50 years and over, and the extra iron load was efficiently removed by therapeutic phlebotomies. However, this disorder also differed from classical hemochromatosis in that transferrin saturation was not consistently increased, and the patients did not exhibit clinical symptoms of iron overload and were M A N U S C R I P T
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heterozygotes for the causing mutations. We propose that a dominant-negative effect of the mutated allele on the processing of the BMP6-WT (as suggested by data in Figure 6 ) might be sufficient to favor iron overload. Indeed, the mature BMP6 protein requires the formation of heteroligomeric complexes with the cleaved propeptide for optimal secretion and trafficking within the cell [19, 26, 27] . Figure S4) . Second, we also observed normal or slightly elevated serum hepcidin levels in BMP6 patients, which were inappropriately low considering the patient iron load. These results are similar to those of previous studies showing the presence of normal or only slightly elevated serum hepcidin levels in HFE-HH patients, despite the presence of excess liver iron [31] [32] [33] . Interestingly, the level of SMAD phosphorylation has also been reported to be inappropriately low in HFE hepatocytes [34] . Together with previously published data, these results highlight the importance of the BMP pathway in iron signaling and hepcidin response in humans. Indeed, a significant association has already been detected between serum ferritin level and a common single-nucleotide polymorphism in the BMP2 genic region in HFE patients [35] and a mutation in the BMP-response element of the HAMP promoter has been observed in patients with HH [36] .
In conclusion, the results of the present study show that these propeptide BMP6 mutations are responsible for inappropriate hepcidin response and mild to moderate iron overload in some patients with so-called unexplained hyperferritinemia. We propose that BMP6 is a new susceptibility gene for iron overload in Caucasians and speculate that it could be the principal susceptibility gene in other ethnic groups where HFE mutations are rarely present The data are mean ± sem (n=4 experiences). *P < 0.05, **P < 0.01, ***P < 0.001. were determined through RT-qPCR. The data were normalized to the levels of β2-microglobulin ( 2M) mRNA and reported as the mean ± sem (n=3 in each experience). *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. 
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